Second engine igniting off the first: an unplanned-for adjacent revenue stream has started paying, and management is now
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript describes a second, distinct way of making money that emerged from existing operations, is already generating real paying business, and management is deliberately growing it. Let's analyze the transcript. The company is Agios, a biotech. They have products: TIBSOVO (ivosidenib) for AML, IDHIFA (enasidenib) for AML, and other pipeline drugs. They also have rare genetic disease programs (Mitapivat for PK deficiency, etc.). The question asks: "does management describe that a SECOND, DISTINCT WAY OF MAKING MONEY has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional revenue avenue that grew out of what the company already does rather than a separate diversification - AND that this second avenue is ALREADY GENERATING REAL PAYING BUSINESS today while management is now deliberately putting effort or resources behind growing it?" We need to look for a second revenue stream that is distinct from the core product sales. For example, licensing, royalties, or something like that. In the transcript, they mention revenue from TIBSOVO sales, IDHIFA royalties, and collaboration revenue. But are those distinct? IDHIFA is a product they developed and licensed to Celgene, so royalties are a revenue stream from that. But is that a "second avenue that grew out of the first"? Actually, IDHIFA is a separate product, not a second avenue from the same product. The question is about a second way of making money that emerged from existing operations, like monetizing a capability, data, etc. Let's read carefully. The transcript mentions: "Total revenue for the third quarter was $15 million, compared to revenue of $11 million for the third quarter of 2017. The year-over-year increase in revenue was driven by $4.5 million of net U.S. sales of TIBSOVO, a $1.3 million increase in the IDHIFA royalty, which was offset by a decrease in collaboration revenue recognized during the quarter." So they have product sales, royalties, and collaboration revenue. But are these distinct "ways of making money" that emerged from existing operations? The royalties from IDHIFA are from a product they developed and licensed. That is a separate product, not a second avenue from the same product.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
LRN · Q1 2019 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows career readiness as a distinct second revenue avenue that emerged directly from the existing MPS business: students already enrolled in Managed Public Schools are being moved into career readiness programs (over 5,000 students), and the initiative is built on the same platform, curriculum, and student base. Management explicitly describes it as a “career readiness line of business” and “robust career readiness business” that is already generating paying enrollments today while they are deliberately investing resources—dedicated executives, reallocation of funds, and plans to drive a major portion of next year’s enrollment growth.
M · Q4 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Macy’s Marketplace is explicitly described as a distinct new revenue avenue that emerged directly from their existing e-commerce operations and customer base (macys.com, cross-shoppers, and omnichannel platform). Jeff Gennette states it “captures incremental sales opportunity,” “drives a larger average order value,” “allows us to quickly move into new and adjacent categories without inventory risk,” and “attracts a new younger customer,” while management is actively scaling it by adding 2,000 brands in 2023 and launching Bloomingdale’s marketplace in the back half.
GDRX · Q2 2022 → YESThe question is: Does management describe a SECOND, DISTINCT WAY OF MAKING MONEY that has recently emerged FROM the company's existing operations, assets, customers, or capabilities - an additional re...YES The transcript shows that Pharma Manufacturer Solutions is the second distinct revenue avenue that emerged from GoodRx’s existing operations. Trevor explicitly states: “Our distinct ability to reach both consumers and providers continues to be recognized by manufacturers as evidenced by the strong growth.” This capability originated from the core prescription-transactions platform and user base 3 years earlier (when other offerings were only ~5% of revenue). In Q2 2022 it generated $26.6 million (102% YoY growth) and is already producing real paying business.